[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 598
Citations 0
News From the Food and Drug Administration
December 1, 2015

New Approaches for Melanoma

JAMA. 2015;314(21):2227. doi:10.1001/jama.2015.15988

The FDA has approved the first oncolytic virus therapy for treating melanoma in the skin and lymph nodes that can’t be surgically removed (http://1.usa.gov/1H8xe3A).

Talimogene laherparepvec, marketed as Imlygic, is a genetically modified herpes simplex virus type 1 designed to replicate within tumors and produce an immunostimulatory protein—granulocyte-macrophage colony-stimulating factor (GM-CSF).

When injected directly into melanoma lesions, talimogene laherparepvec causes tumors to rupture and die. The process releases tumor-derived antigens that, together with GM-CSF, may promote an antitumor immune response. However, investigators are still working to determine the drug’s exact mechanism of action.

First Page Preview View Large
First page PDF preview
First page PDF preview
×